Search the Newsreel

Bridgepoint Group plc (BPT) Announces Issuance of 10.1 Million Shares to Fulfill ECP Transaction Vesting Awards

StoneBridge Acquisition II Ord Shs Class A (APAC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Corebridge Financial, Inc. (CRBG) Receives a Buy from KBW

Chain Bridge Bancorp, Inc. (NYSE:CBNA) Receives Average Rating of "Reduce" from Brokerages

Chain Bridge Bancorp, Inc. (NYSE:CBNA) has received a consensus "Reduce" rating from brokerages, with an average 12-month price target of $42.17, which is below its recent trading price of $47.88. Despite this, the company recently surpassed earnings and revenue expectations, reporting $1.45 per share …

Will Bridgemarq Real Estate Services Inc (BRE) Beat Earnings Estimates in Its Next Report?

Bridgford Foods Corp (BRID) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Bridgford Foods Corp (BRID), including future EPS and revenue growth estimates. It lists BRID's current stock price, market capitalization, and links to various financial data sections on TradingKey. The content also includes a peer comparison for Bridgford …

Enbridge Inc (ENB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Corebridge Financial Inc (CRBG) Earnings Forecast: Future EPS & Revenue Growth Estimates

Village Farms International And 2 Other Penny Stocks Worth Watching

This article highlights three penny stocks—Village Farms International (VFF), NovaBridge Biosciences (NBP), and Quanterix (QTRX)—as potential investment opportunities. It details each company's financial health, operational focus, recent performance, and growth prospects, emphasizing their unique positions within their respective markets. The market as a whole …

LIGHTBRIDGE Corp (LTBR) director sells 15,000 shares at $8.99 average price

Mark Robert Tobin, a director at LIGHTBRIDGE Corp (LTBR), sold 15,000 shares of common stock on August 11, 2026, at a weighted average price of $8.99 per share. The transaction was an open-market sale, and following this, Tobin directly holds 66,669 shares of the …

Corebridge Financial (CRBG) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026, at 9 a.m. ET CALL PARTICIPANTS Head of Investor and Rating Agency Relations - Isil MuderrisogluPresident and Chief Executive Officer - Marc CostantiniInterim Chief Financial Officer - Chris FiliaggiChief Investment Officer - Lisa Longino …

David Capobianco sells $93.8 million LandBridge (LB) shares

David N. Capobianco, a director and 10% owner of LandBridge Co LLC, sold 1,250,000 Class A shares for $93.8 million on August 7, 2026, at $75.05 per share. The stock has since risen to $83.91, up 11.8% from the sale price. This transaction followed …

BridgeBio Pharma (BBIO) Stock Rally Leans On Attruby As Losses Recede

BridgeBio Pharma's stock saw a modest pullback despite strong Q2 2026 results driven by significant revenue from its flagship drug Attruby, which accounted for the majority of its $243.7 million quarterly revenue. While losses narrowed and pipeline milestones were achieved, concerns remain about the …

Bridgeline Digital Q3 Results: Earnings Call Set for Aug 13

Bridgeline Digital, Inc. will announce its Q3 fiscal 2026 financial results after market close on August 13, 2026. CEO Ari Kahn and CFO Thomas Windhausen will host a conference call at 4:30 p.m. ET to discuss the results, and investors are encouraged to register …

BridgeBio Earnings: Strong Attruby Uptake as Late-Stage Candidates Are Under Regulatory Review

Bridgeline to Report Financial Results for the Third Quarter of Fiscal 2026

Bridgeline Digital, Inc. announced it will release its financial results for the third quarter of fiscal 2026 after market close on Thursday, August 13, 2026. The company's President and CEO, Ari Kahn, and CFO, Thomas Windhausen, will host a live conference call at 4:30 …

Two July Hires Receive Options on 65,350 BridgeBio Shares

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced it granted inducement equity awards on August 10, 2026, to two new employees hired in July 2026. These employees received non-qualified stock options for an aggregate of 65,350 shares of common stock at an exercise price of $9.28 …

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (BBOT) announced inducement grants of non-qualified stock options to two new employees hired in July 2026. These grants, totaling 65,350 shares at an exercise price of $9.28 per share, were made under BBOT’s 2025 Inducement Plan and approved in accordance with …

Enbridge Stock: Should You Buy, Sell, or Hold Right Now?

Enbridge stock is currently down over 10% from its 2026 high, trading near $71 per share. This dip is attributed to factors like the delay of its Mainline oil pipeline expansion, the rejection of a Line 5 tunnel permit, and potential future interest rate …

BridgeBio’s 56 New Employees Get Awards With Vesting Starting in 2027

BridgeBio Pharma announced equity inducement grants of 66,705 restricted stock units to 56 new employees, with the first quarter vesting on August 16, 2027. These grants are part of an employment inducement plan under Nasdaq Listing Rule 5635(c)(4). The company aims to develop transformative …

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) doubles R&D spend, logs $98.6M loss

Lightbridge Corporation (LTBR) files Form 144 for sale of 15,000 shares

Lightbridge Corporation has filed a Form 144 with the SEC, announcing a proposed sale of 15,000 shares of common stock through Jefferies LLC. The aggregate market value of these shares is $134,910.00 as of August 11, 2026. The filing also details prior restricted stock …

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio's board …

Bank of America Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. Stock 12‑Month Price Target Raised to $109.44, Implies 29% Upside

BridgeBio Pharma, Inc.'s stock (BBIO) has seen its average 12-month price target raised from $107.65 to $109.18 by 19 analysts, implying a potential 29% upside from its Aug. 10 closing price. The consensus rating for BBIO remains a "Buy" among 23 analysts, with 21 …

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)

BridgeBio Pharma reported strong Q2 results, exceeding analyst expectations and reaffirming its guidance for Attruby/Beyonttra global sales to surpass $1 billion this year. The company saw a significant surge in Attruby's U.S. net sales and increased Beyonttra royalties, indicating growing market share. BridgeBio's recent …

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma (BBIO) reported a wider-than-expected Q2 2026 loss of 78 cents per share but saw revenues surge 120% year over year to $243.7 million, beating estimates, primarily driven by strong sales of its drug Attruby. The company is also advancing multiple late-stage pipeline …

Enbridge Inc. stock rises Tuesday, outperforms market

Enbridge Inc. (ENB) stock increased by 0.20% on Tuesday, closing at C$71.85, outperforming the S&P/TSX Composite Index which rose 0.05%. The company's stock is currently 10.9% below its 52-week high of C$80.65, achieved on May 22nd.

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, TD Cowen Analyst Says

Morgan Stanley Has Lowered Expectations for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

Corebridge Financial (NYSE:CRBG) Shares Gap Down - Here's Why

Why Bridgemarq Real Estate Services Inc stock is rising today

BRIDGEBIO PHARMA, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $107 FROM $102

Truist Securities has increased its target price for BridgeBio Pharma, Inc. (BBIO.O) from $102 to $107. The news was reported by Reuters. This adjustment reflects an updated outlook on the company's valuation by the financial institution.

Wells Fargo raises BridgeBio Pharma stock price target on launch outlook

Wells Fargo has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $102 from $98, maintaining an Overweight rating due to anticipated near-term launches. Despite an 11% year-to-date gain, the stock is considered slightly overvalued. The firm expects further upside after detailed CARDIO-Transform data …

Enbridge's Profit Just Fell 7%. Here's Why That's Not the Real Story.

Midstream operator Enbridge (NYSE: ENB) reported earnings on July 31, and its stock has tumbled more than 7% since. The reason was obvious. The company's profit margin narrowed because its heavy debt load is weighing on net earnings. Enbridge reported earnings per share (EPS) …

Clearbridge Health Reconstitutes Board Following Director’s Cessation